Jan 10, 2024

Public workspaceBrimblecombe, K.R. et al. (2023) Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine, co-varies with risk factors for Parkinson’s. V.3

DOI
dx.doi.org/10.17504/protocols.io.4r3l27dxxg1y/v3
  • 1Department of Physiology, Anatomy and Genetics, University of Oxford, OX1 3PT, UK;
  • 2Oxford Parkinson’s Disease Centre, University of Oxford, Oxford, United Kingdom;
  • 3Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, MD, 20815
Cláudia C. Mendes
Icon indicating open access to content
QR code linking to this content
DOI: dx.doi.org/10.17504/protocols.io.4r3l27dxxg1y/v3
Collection Citation: Katherine Brimblecombe, Stephanie J Cragg 2024. Brimblecombe, K.R. et al. (2023) Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine, co-varies with risk factors for Parkinson’s. . protocols.io https://dx.doi.org/10.17504/protocols.io.4r3l27dxxg1y/v3Version created by Cláudia C. Mendes
Manuscript citation:
Brimblecombe KR, Connor-Robson N, Bataille CJR, Roberts BM, Gracie C, O'Connor B, Te Water Naude R, Karthik G, Russell AJ, Wade-Martins R, Cragg SJ. Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine co-varies with risk factors for Parkinson's. Eur J Neurosci. 2023 Nov 8. doi: 10.1111/ejn.16180. Epub ahead of print. PMID: 37941514.
License: This is an open access collection distributed under the terms of the Creative Commons Attribution License,  which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Protocol status: Working
We use this collection and it's working
Created: January 10, 2024
Last Modified: January 10, 2024
Collection Integer ID: 93218
Keywords: Calb1, L-type calcium channel, Parkinson's disease, dopamine D2 receptor, dopamine release, dopamine transporter, sex differences, striatum, synuclein
Funders Acknowledgements:
Aligning Science Across Parkinson’s
Grant ID: ASAP-020370
Abstract
This collection contains five protocols detailing methods used in Brimblecombe, K.R. et al. (2023) Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine, co-varies with risk factors for Parkinson’s.
Files
Protocol
Icon representing the file Fast-scan cyclic voltammetry to assess dopamine release in ex vivo mouse brain slices
Name
Fast-scan cyclic voltammetry to assess dopamine release in ex vivo mouse brain slices
Version 1
, University of Oxford
Cláudia C. MendesUniversity of Oxford
Protocol
Icon representing the file Making Carbon-Fibre Microelectrode (CFM) for electrochemical recordings of monoamines in ex vivo mouse brain slices
Name
Making Carbon-Fibre Microelectrode (CFM) for electrochemical recordings of monoamines in ex vivo mouse brain slices
Version 2
, University of Oxford
Cláudia C. MendesUniversity of Oxford
Protocol
Icon representing the file Synthesis of 1-(3-chlorophenethyl)-3-cyclopentylpyrimidine-2,4,6-(1H,3H,5H)-trione (CP8)
Name
Synthesis of 1-(3-chlorophenethyl)-3-cyclopentylpyrimidine-2,4,6-(1H,3H,5H)-trione (CP8)
Version 2
, University of Oxford
Cláudia C. MendesUniversity of Oxford
Protocol
Icon representing the file Stock solutions of cocaine, isradipine, nomifensine, lidocaine, DHβE, CP8, L-741,626, and water-soluble cholesterol
Name
Stock solutions of cocaine, isradipine, nomifensine, lidocaine, DHβE, CP8, L-741,626, and water-soluble cholesterol
Version 1
, University of Oxford
Cláudia C. MendesUniversity of Oxford
Protocol
Icon representing the file Western blot in homogenised mouse brain samples
Name
Western blot in homogenised mouse brain samples
Version 2
, University of Oxford
Cláudia C. MendesUniversity of Oxford